Tiragolumab, an anti-TIGIT antibody in association with atezolizumab has been evaluated in the CITYSCAPE study, a phase II trial conducted on patients with PD-L1 positive NSCLC [107]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.